Porcine adeno-associated viruses

Abstract

Porcine tissues were screened for the presence of Adeno-Associated Viruses (AAV). Several AAV sequences were isolated from various porcine tissues, and BLAST analysis confirmed high to low homology with known AAV sequences of different origin. Sequence analysis confirmed the isolation of at least three novel porcine AAV isolates which we named AAVpo1, -po2, and -po3. Novel AAVs derived from porcine tissues may significantly contribute to the generation of new preventive or curative clinical modalities acceptable for human use.

The invention claimed is: 
     
       1. A method for the preparation of a recombinant porcine adeno-associated virus (AAV) particle comprising:
 providing a cell engineered to express:
 porcine AAV capsid protein VP1 consisting of the amino acid sequence as set forth in SEQ ID NO:24; 
 porcine AAV capsid protein VP2 consisting of the amino acid sequence as set forth in SEQ ID NO: 25; 
 porcine AAV capsid protein VP3 consisting of the amino acid sequence as set forth in SEQ ID NO:26; 
 a minigene comprising two AAV inverted terminal repeats and a transgene inserted between the two inverted terminal repeats; and 
 a functional rep gene compatible with said AAV inverted terminal repeats; 
 sufficient helper functions to permit packaging of the minigene into a porcine AAV capsid particle; and 
 
 recovering said recombinant particle from said cell. 
 
     
     
       2. A single dose, injectable pharmaceutical composition comprising 1×10 9 -1×10 13  purified recombinant AAV particles prepared according to the method of  claim 1  and a suitable excipient.